H.U. Group Holdings Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (hereinafter ¡°Fujirebio¡±) today announced that Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio, has acquired all shares of Plasma Services Group, Inc. (hereinafter ¡°Plasma Services Group¡±). The transaction value has not been disclosed.

Roche¡¯s Largest Investment in China Breaks Ground with Initial Funding of RMB 3 Billion Recently, Roche Diagnostics (Suzhou) Co., Ltd. successfully obtained the construction permit for it..

Amazon has launched its first-ever at-home lab testing service in India. The new service, called Amazon Diagnostics, has been introduced in collaboration with Orange Health Labs, a diagnostics provider known for its convenience-focused model.

The European Commission decided to exclude Chinese companies from EU government purchases of medical devices exceeding €5 million. This measure follows the conclusions of the first investigation under the International Procurement Instrument (IPI), and allows no more than 50% of inputs from China for successful bids.

In a letter to customers on Wednesday, Bio-Rad Laboratories announced that it has decided against implementing a tariff surcharge that the company on May 21 said it was considering for at least some of its products. The surcharge came following the firm's disclosure of approximately $40 million in tariff-related revenue headwinds for 2025.

GeneCentric Therapeutics, a company making precision medicine more precise through gene expression, today announced the initial closing of an $8.0 million Series C financing. The proceeds will be used to launch and commercialize GeneCentric¡¯s GenomicsNext™, the first integrated platform for comprehensive liquid biopsy testing that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from circulating tumor DNA (ctDNA) in one sample.

Original from: business wire ¡¤ GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development ¡¤ GENCURIX signs as inaugural par..

Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (¡°SciBase¡±) utilizing SciBase¡¯s Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments.

4. Biochip Technology Biochips enable the accurate, rapid, and high-throughput detection of DNA, RNA, polypeptides, proteins, cells, tissues, and other biological components, with great advantages in disease scr..

Revvity and ReliableMed Forge Strategic Partnership to Focus on Newborn Screening and Early Diagnosis of Rare Diseases Recently, ReliableMed announced a major strategic partnership with R..

Original from: PR Newswire ¡¤ The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), other..

bioM¨¦rieux, a world leader in the field of in vitro diagnostics, announces an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance bioM¨¦rieux's capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions.

University of Chicago spinout OrisDx said Tuesday that it has raised $4 million in seed funding and it will use the money to support the launch of its saliva-based molecular test for oral cancers.

Original from: businesswire ¡¤ QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies ..